Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_2
2
50%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting2
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

active_not_recruiting250%
recruiting125%
completed125%

Recent Activity

3 active trials
Showing 4 of 4
active_not_recruitingphase_2

Pembrolizumab Plus Olaparib in LA-HNSCC

NCT05366166
active_not_recruitingphase_1

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

NCT03212742
recruitingnot_applicable

IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer

NCT06630793
completedphase_2

Chemoradiation or Brachytherapy for Rectal Cancer

NCT02017704

Clinical Trials (4)

Showing 4 of 4 trials
NCT05366166Phase 2

Pembrolizumab Plus Olaparib in LA-HNSCC

Active Not Recruiting
NCT03212742Phase 1

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active Not Recruiting
NCT06630793Not Applicable

IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer

Recruiting
NCT02017704Phase 2

Chemoradiation or Brachytherapy for Rectal Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4